Up next

Autoplay

Dr. Moskowitz on the ALCANZA Trial in CTCL

4 Views • 08/09/23
Share
Embed
administrator
administrator
Subscribers
0

Alison J. Moskowitz, MD, clinical director, Lymphoma Inpatient Unit, Memorial Sloan Kettering Cancer Center, discusses the data that led to the approval of brentuximab vedotin (Adcetris) in patients with cutaneous T-cell lymphoma (CTCL).

Show more
0 Comments sort Sort By
Facebook Comments

Up next

Autoplay